Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;16(4):197-206.
doi: 10.1097/CU9.0000000000000145. Epub 2022 Aug 31.

Prostate cancer screening: Continued controversies and novel biomarker advancements

Atiyah Tidd-Johnson  1   2 , Sneha Annie Sebastian  1 , Edzel Lorraine Co  1 , Munaza Afaq  1 , Hansini Kochhar  1 , Mona Sheikh  1 , Arpit Mago  1 , Sujan Poudel  1 , John A Fernandez  1   3 , Ivan D Rodriguez  1   4 , Sanjay Razdan  1   5   6
Affiliations

Prostate cancer screening: Continued controversies and novel biomarker advancements

Atiyah Tidd-Johnson et al. Curr Urol. 2022 Dec.

Abstract

Prostate cancer (PCa) screening remains one of the most controversial topics in clinical and public health. Despite being the second most common cancer in men worldwide, recommendations for screening using prostate-specific antigen (PSA) are unclear. Early detection and the resulting postscreening treatment lead to overdiagnosis and overtreatment of otherwise indolent cases. In addition, several unwanted harms are associated with PCa screening process. This literature review focuses on the limitations of PSA-specific PCa screening, reasons behind the screening controversy, and the novel biomarkers and advanced innovative methodologies that improve the limitations of traditional screening using PSA. With the verdict of whether or not to screen not yet unanimous, we hope to aid in resolution of the long-standing debate.

Keywords: Biopsy; Liquid biopsy; Multiparametric magnetic resonance imaging; Novel biomarkers; Prostate cancer; Prostate cancer screening; Prostate-specific antigen; Tumor markers.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest has been declared by the author.

References

    1. Catalona WJ. Prostate cancer screening. Med Clin North Am 2018;102(2):199–214. - PMC - PubMed
    1. Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 2022;10:811044. - PMC - PubMed
    1. American Cancer Society . Key statistics for prostate cancer. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf. Accessed May 5, 2022.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71(1):7–33. - PubMed
    1. Sung H Ferlay J Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. - PubMed